Labcorp Holdings (LH) Expands HPV Testing While Teaming With Regulators On Drug Safety

• Labcorp Holdings (NYSE: LH) partnered with Waters Corporation to deploy the BD Onclarity HPV Assay across its national laboratory network.

• The BD Onclarity HPV Assay rollout is designed to broaden access to advanced cervical cancer screening for patients across the United States.

• Labcorp announced a collaboration with the FDA and Charles River Laboratories to refine methods used to evaluate drug abuse potential.

• These moves on BD Onclarity HPV testing and drug abuse potential assessment only capture part of what is changing for Labcorp. Check out 1 warning sign that Labcorp Holdings investors should know about.

This focus on diagnostics and drug safety is shared by a wider group of healthcare players that you can review through 36 healthcare AI stocks .

Labcorp Holdings, a US-based provider of laboratory services with a market capitalization of about $26.9b, occupies a central role in diagnostic testing that supports both patient care and pharmaceutical research decisions related to products such as HPV assays and drug abuse potential studies.

2 things going right for Labcorp Holdings that this headline doesn't cover.

Labcorp's diagnostics push supports the long term healthcare testing story

For investors, the Waters HPV partnership and the FDA collaboration on abuse potential research both reinforce Labcorp's pitch as a diagnostics and drug development partner, not just a volume testing provider. The moves line up with recent Q3 2026 results and the raised 2026 revenue growth guidance to 5.9% to 6.7% because they speak to where future test mix and client relationships could come from. The work with BD Onclarity HPV and with regulators also supports the idea that Labcorp's scale in specialty assays and regulatory grade studies is a central part of its competitive position.

The unresolved issue is whether these programs translate into attractive returns after reimbursement changes and Labcorp's debt load are taken into account. The practical checkpoint is late 2026 and early 2027. Investors can watch for concrete volumes and revenue contributions from BD Onclarity HPV testing, plus updated contract wins tied to the abuse potential research, to see if this news is moving the needle.

Labcorp has one more piece hiding in plain sight who is actually in charge and what they get paid to call the shots

Ownership, test mix and guidance only tell part of the story, because the real steering wheel sits with the executives and board setting pay incentives. See who is actually steering Labcorp Holdings, and how they are paid .